 |
|
Tiny but toxic: MBL researchers discover a mechanism of neurodegeneration in Alzheimer's disease
March 27, 2009WOODS HOLE, MA-Tiny, toxic protein particles severely disrupt neurotransmission and inhibit delivery of key proteins in Alzheimer's disease, two separate studies by Marine Biological Laboratory (MBL) researchers have found.
The particles are minute clumps of amyloid beta, which has long been known to accumulate and form plaques in the brain of Alzheimer's patients.
"These small particles that haven't aggregated into plaques-these are increasingly being seen as the really toxic species of amyloid beta," says Scott Brady of University of Illinois College of Medicine, who has been an MBL investigator since 1982.
Brady and his colleagues found that these particles inhibit neurons from communicating with each other and with other target cells in the body.
"The disease symptoms for Alzheimer's are associated not with the death of the neurons - that is a very late event - but with the loss of functional connections. It's when the neuron is no longer talking to its targets that you start to get the memory deficits and dementia associated with the disease," Brady says.
The amyloid beta particles activate an enzyme, CK2, which in turn disrupts the "fast axonal transport" system inside the neuron, Brady found. This transport system has motor proteins that move various kinds of cargo (including neurotransmitters and the associated protein machinery for their release) from place to place in the neuron on microtubule tracks.
Brady's findings are complemented by a new study by Rudolfo Llinás of New York University School of Medicine. Brady and Llinás both conduct neuroscience research at the MBL using the giant nerve cell of the Woods Hole squid, Loligo paeleii, as a model system.
Llinás found that activation of CK2 blocks neurotransmission at the synapse - the point where the neuron connects to its target.
"Disruptions in the fast axonal transport system are probably key elements in the pathogenesis of Alzheimer's and other adult-onset neurodegenerative diseases, such as Parkinson's and ALS," says Brady. "It doesn't mean that is the only thing going on, or that it is the triggering feature of the disease. But we do know that changes in the fast axonal transport system are sufficient to cause the 'dying back' of neurons that is characteristic of these diseases."
The new findings suggest the possibility of designing a drug to inhibit CK2 activation in Alzheimer's patients. However, a prior study by Brady found that activation of another enzyme, GSK3, in Alzheimer's also disrupts the fast axonal transport system. It may therefore be necessary to inhibit both enzymes.
"There haven't yet been any therapies designed for Alzheimer's with the idea of protecting the fast axonal transport system," says Brady. "But if there were, they would have to inhibit the activation of both CK2 and GSK3. We can't think of it as a single thing going wrong. There are several things going wrong."
Marine Biological Laboratory
Brady and his colleagues found that these particles inhibit neurons from communicating with each other and with other target cells in the body.
"The disease symptoms for Alzheimer's are associated not with the death of the neurons - that is a very late event - but with the loss of functional connections. It's when the neuron is no longer talking to its targets that you start to get the memory deficits and dementia associated with the disease," Brady says.
The amyloid beta particles activate an enzyme, CK2, which in turn disrupts the "fast axonal transport" system inside the neuron, Brady found. This transport system has motor proteins that move various kinds of cargo (including neurotransmitters and the associated protein machinery for their release) from place to place in the neuron on microtubule tracks.
Brady's findings are complemented by a new study by Rudolfo Llinás of New York University School of Medicine. Brady and Llinás both conduct neuroscience research at the MBL using the giant nerve cell of the Woods Hole squid, Loligo paeleii, as a model system.
Llinás found that activation of CK2 blocks neurotransmission at the synapse - the point where the neuron connects to its target.
"Disruptions in the fast axonal transport system are probably key elements in the pathogenesis of Alzheimer's and other adult-onset neurodegenerative diseases, such as Parkinson's and ALS," says Brady. "It doesn't mean that is the only thing going on, or that it is the triggering feature of the disease. But we do know that changes in the fast axonal transport system are sufficient to cause the 'dying back' of neurons that is characteristic of these diseases."
The new findings suggest the possibility of designing a drug to inhibit CK2 activation in Alzheimer's patients. However, a prior study by Brady found that activation of another enzyme, GSK3, in Alzheimer's also disrupts the fast axonal transport system. It may therefore be necessary to inhibit both enzymes.
"There haven't yet been any therapies designed for Alzheimer's with the idea of protecting the fast axonal transport system," says Brady. "But if there were, they would have to inhibit the activation of both CK2 and GSK3. We can't think of it as a single thing going wrong. There are several things going wrong."
Marine Biological Laboratory
Neurodegeneration Current Events and Neurodegeneration News RSSSchizophrenia gene's role may be broader, more potent, than thought
UCSF scientists studying nerve cells in fruit flies have uncovered a new function for a gene whose human equivalent may play a critical role in schizophrenia.
Research reveals lipids' unexpected role in triggering death of brain cells
The lipid that accumulates in brain cells of individuals with an inherited enzyme disorder also drives the cell death that is a hallmark of the disease, according to new research led by St. Jude Children's Research Hospital investigators.
Statins show dramatic drug and cell dependent effects in the brain
Besides their tremendous value in treating high cholesterol and lowering the risk of heart disease, statins have also been reported to potentially lower the risks of other diseases, such as dementia.
Trembling hands and molecular handshakes
Fragile X tremor/ataxia syndrome (FXTAS) is a recently recognized condition, which is actually one of the most prevalent heritable neurodegenerative diseases.
Alzheimer's researchers find high protein diet shrinks brain
One of the many reasons to pick a low-calorie, low-fat diet rich in vegetables, fruits, and fish is that a host of epidemiological studies have suggested that such a diet may delay the onset or slow the progression of Alzheimer's disease (AD).
Study examines treatment for olfactory loss after viral infection
Treatment with a glucocorticoid medication, either alone or in combination with Ginkgo biloba, appears to significantly improve the sense of smell in individuals with previous olfactory loss due to upper respiratory infections.
How Proteins Talk to Each Other
Investigators at Burnham Institute for Medical Research (Burnham) have identified novel cleavage sites for the enzyme caspase-3 (an enzyme that proteolytically cleaves target proteins).
Reactive Oxygen's Role in Metastasis
Researchers at the Burnham Institute for Medical Research (Burnham) have discovered that reactive oxygen species, such as superoxide and hydrogen peroxide, play a key role in forming invadopodia, cellular protrusions implicated in cancer cell migration and tumor metastasis.
New Insights Into Cardiac Aging
Investigators at Burnham Institute for Medical Research (Burnham) have found that the conserved protein d4eBP modulates cardiac aging in Drosophila (fruit flies).
When Proteins Change Partners
Dieter Wolf, M.D., and colleagues at Burnham Institute for Medical Research (Burnham) have illuminated how competition between proteins enhances combinatorial diversity during ubiquitination (the process that marks proteins for destruction).
More Neurodegeneration Current Events and Neurodegeneration News Articles
 |
The Proteasome in Neurodegeneration by Leonidas Stefanis (Editor), J.N. Keller (Editor) There is increasing evidence that links together various common neurodegenerative diseases, such as Parkinson’s and Alzheimer’s diseases. Finding common themes in the pathophysiology of such disorders is increasingly important. This text addresses such a common theme—the proteasome. Since the discovery of the proteasome some 20 years ago, significant strides have been made in our understanding of proteasome biology and our understanding of the role the proteasome plays in a wide variety of biochemical events. Taken together, these studies have confirmed an important role for the proteasome in the fields of cell biology, oncology, immunology, gerontology, and neuroscience. The focus of this book is to provide an in depth analysis and provocative discussion of what... |
 |
Advances in Research on Neurodegeneration: Volume 10 (Advances in Research on Neurodegeneration, 10) by R. Horowski (Editor), Y. Mizuno (Editor), C.W. Olanow (Editor), W. Poewe (Editor), P. Riederer (Editor), J.A. Stoessel (Editor), M.B.H. Youdim (Editor) Neurobiotec, Berlin, Germany. Presents the proceedings from the 10th International Winter Conference on Neurodegeneration, held in Berlin, Germany, February 14-16, 2002. |
 |
Metal-based Neurodegeneration: From Molecular Mechanisms to Therapeutic Strategies by Robert Crichton (Author), Roberta Ward (Author) This exciting new book opens a window into the causes of debilitating neurological disorders such as Parkinson’s disease, CJD and Huntington’s disease, and gives indications of the prospects for therapy, based on the understanding of molecular defects involved in these diseases. Looking at each specific neurological disorder in turn, the book outlines the role of metals in human biology, in particular in the brain and explores tools for testing potential therapeutic strategies. It concludes with an overview of the potential of both chelation and antioxidant therapy and outlines some perspectives for the future. |
 |
Neurodegeneration Methods and Protocols (Methods in Molecular Medicine) by Jean Harry (Editor), Hugh A. Tilson (Editor) Techniques for studying many aspects of nervous system cell biology. Contains notes about potential pitfalls and tips on how to avoid failures. Modified-outline format. DNLM: Nerve Degeneration. |
 |
Neurodegeneration and Prion Disease by David R. Brown (Editor) This volume provides an in-depth overview from world experts on prion disease. These fatal diseases include Creutzfeldt-Jakob disease, chronic wasting disease in deer, scrapie of sheep, bovine spongiform encephalopathy (mad cow’s disease) of cattle and related diseases. Understanding what causes neuronal death in these diseases is essential to both preventing and curing them. The most recent advances in understanding neuronal death in prion diseases are presented. Prion diseases serve as an experimental model for all neurodegenerative conditions. This book will provide understanding of neurodegeneration and provide an up-to-date record of the state of the art for other specialists and non-specialists in related fields. |
 |
New Perspectives on Brain Cell Damage, Neurodegeneration and Neuroprotective Strategies 2007 by Editor-in-Chief: Abel Santamaria (Author), Associate Editor: Maria Esther Jimenez-Capdeville (Author), Editor-in-Chief: Abel Santamaria (Editor) From the Preface For the last four decades, the study of the functioning and pathological alterations of the Nervous System has been intensified in search for therapeutic alternatives against neurodegenerative disorders in humans. Since their first descriptions in the 19th and 20th centuries, sufficient clinical and experimental findings contributed to describe the origin of some of the most common and frequent neurological diseases. Derived from this multidisciplinary research performed along decades, now we know that a great number of factors trigger nerve tissue damage and cell death, and they include the environmental exposure to toxicants, inheritance patterns, the individual susceptibility to endogenous or exogenous neurotoxins, ageing processes, traumatic injury, drug... |
 |
Progress in Neurodegeneration: The Role of Metals (Neurodegenerative Diseases-Laboratory and Clinical Research Series) by Maria Rosa Avila-Costa (Editor), Veronica Anaya Martinez (Editor) This book highlights the role of some metals which induce oxidative stress and imbalances in the neurodegenerative diseases such as Alzheimer disease, Parkinson disease, Amyotrophic Lateral Sclerosis, Huntington Disease, and other dementias. The chemistry and biochemistry of metals induced-oxidative stress, protein damage is first described, followed by the evidence for a pathological role of oxidative stress in these disease states. It is tempting to speculate that free radical oxygen chemistry contributes to pathogenesis in all these conditions, though it is as yet undetermined what types of oxidative changes occur early in the disease, and what types are secondary manifestations of neuronal degeneration. Finally the authors review different metals to describe their specific role in the... |
|
[[alpha].sub.1A] adrenergic receptor regulation of seizures & neurodegeneration.(COMMUNICATIONS--GRADUATE): An article from: Proceedings of the North Dakota Academy of Science by Jessica A. Lichter (Author), Christopher A. Knudson (Author), Chris W.D. Jurgens (Author), Patrick A. Carr (Author), Dianne M. Perez (Author), Van A. Doze (Author) This digital document is an article from Proceedings of the North Dakota Academy of Science, published by North Dakota Academy of Science on April 1, 2007. The length of the article is 503 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: [[alpha].sub.1A] adrenergic receptor regulation of seizures & neurodegeneration.(COMMUNICATIONS--GRADUATE) Author: Jessica A. Lichter Publication: Proceedings of the North Dakota Academy of Science (Magazine/Journal) Date: April 1, 2007 Publisher: North Dakota Academy of Science Volume: 61 Page: 35(1) Distributed by Gale, a part of Cengage... | |
 |
Frontiers in Clinical Neuroscience: Neurodegeneration and Neuroprotection (Advances in Experimental Medicine and Biology) by Laszlo Vecsei (Editor) This is a special proceedings - "Frontiers in Clinical Neuroscience: 2002" - held in Abel Lajtha's honor. Professor Lajtha is a well-known supporter of Hungarian science and he is celebrating his 80th birthday this year. Professor Vecsei is the secretary for the European Society for Clinical Neuropharmacology and the Danube Symposium for Neurological Sciences. The proceedings will focus on neurodegeneration and neuroprotection, two current topics in clinical and experimental neuroscience. |
|
Power Cracking of Cash Cord Codes / Flies Carry Gene for Alcohol Sensitivity / Unveiling the Tau of Neurodegeneration / Protein's Shape May Give Extra-Sugary Taste / Computer Model Captures Missing Matter / Healthy Functioning Takes Social Cues (Science News, Volume 153, Number 25, June 20, 1998) by Julie Ann Miller (Editor) |
| © 2009 BrightSurf.com |